Table 3.

List of studies reporting the analysis of circulating free DNA in hepatocellular carcinoma (HCC) patients (2017–2018): sensitivity, specificity, and area under the ROC curve.

Study	Number of Patients	Comparison/Control Patients (Number)	DNA Methylation	Se1	Sp2	AUC	Reference
Dong 2017	343	98 HCC 75 liver cirrhosis 90 chronic hepatitis B 80 healthy individuals	APC	36.7	96.4	0.650	[16]
			RASSF1A	52	91.5	0.718
			BVES	29.6	97.6	0.636
			TIMP3	11.2	98.8	0.356
			GSTP1	17.4	98.7	0.486
			HOXa9	20.4	95.8	0.521
			RASSF1A + BVES + HOXa9	83.7	78.9	0.852
Lu 2017	357	Hepatitis B virus (HBV)-related HCC HBV-related HCC with cirrhosis HCV-related HCC Hepatitis C virus (HCV)-related HCC with cirrhosis HCC without HBV or HCV	APC	-	-	0.644	[17]
			COX2	-	-	0.758
			RASSF1A	-	-	0.666
			APC + COX2 + RASSF1A + miR-203	-	-	0.87
Huang 2018	326	119 HCC 105 liver cirrhosis 52 benign lesion patients 50 healthy people	SFRP1	56.3	26	0.65	[20]
			LINE-1	50.0	8.2	0.70
			P16	59.4	31.5	0.63
			SFRP1 + LINE-1 + P16	93.8	63.0	0.86
Tao 2018	135	80 HBV-related HCC 35 chronic hepatitis B 20 healthy controls	IGFBP7	60.0	77.14	0.695	[19]
Tian 2018	193	20 HCC 146 chronic hepatitis B 27 healthy controls	HCCS1	62.5	83.6	0.730	[21]
			HCCS1+AFP	81.7	52.1	0.713
Oussalah 2018	289	289 cirrhosis of which 98 had HCC	SEPT9	98	64.4	0.94	[48]
Wei 2017	116	48 HCC 48 non-tumor 10 liver cirrhosis 6 benign lesions 4 normal liver	SOCS3	73.9			[23]
Wu 2017	494	237 HCC 257 control individuals	CDKN29	-	-	-	[18]
			STEAP4	-	-	-
			ZNF154	-	-	-
			TBX2	-	-	0.61
			VIM	-	-	-
			RASSF1A	-	-	-

¹ SE = sensitivity ² SP = specificity.